49. Systemic lupus erythematosus Clinical trials / Disease details
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04486118 (ClinicalTrials.gov) | October 1, 2021 | 28/10/2019 | Centrally Acting ACE Inhibition in SLE | A Novel Phase 2 Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy of Centrally Acting, Non-toxic ACE Inhibition in Cognitive Impairment Associated With SLE | Systemic Lupus Erythematosus | Drug: Lisinopril Pills;Drug: Benazepril Pill | Northwell Health | Lupus Research Alliance | Recruiting | 18 Years | 55 Years | All | 36 | Phase 2 | United States |